The value of kidney injury molecule 1 in predicting acute kidney injury in adult patients: a systematic review and Bayesian meta-analysis.

The value of kidney injury molecule 1 in predicting acute kidney injury in adult patients: a systematic review and Bayesian meta-analysis.
复制标题

肾损伤分子1在预测成人急性肾损伤中的价值:一项系统回顾和贝叶斯荟萃分析。

DOI:
10.1186/s12967-021-02776-8
复制
发表时间:
2021-03-12
影响因子:
7.4
通讯作者:
Su B
Su B
中科院分区:
医学2区
文献类型:
--
作者:
Geng J;Qiu Y;Qin Z;Su B

文献摘要

参考文献

被引文献

相似文献

本研究的目的是系统回顾相关研究,以评估尿肾损伤分子1(uKIM-1)对成人急性肾损伤(阿基)的诊断价值。我们检索了PubMed和Embase中截至2019年11月1日发表的文献,并使用诊断准确性研究质量评估工具(QUADAS-2)评估质量。然后,我们从每个合格的研究中提取有用的信息,并汇总灵敏度,特异性和曲线下面积(AUC)值。共纳入14项研究,3300例患者。尿KIM-1(uKIM-1)诊断阿基的敏感性为0.74(95%CrI,0.62-0.84),特异性为0.84(95%CrI,0.76-0.90)。合并诊断比值比(DOR)为15.22(95%CrI,6.74-42.20),RD为0.55(95%CrI 0.43-0.70),uKIM-1诊断阿基的AUC为0.62(95%CrI 0.41-0.76)。亚组分析的结果显示了不同因素的影响。尿KIM-1是成人阿基的良好预测指标,具有相对较高的敏感性和特异性。然而,uKIM-1是否以及如何在临床诊断中普遍使用,仍需要进一步的研究和临床试验来证实。
The aim of the study was to systematically review relevant studies to evaluate the diagnostic value of urinary kidney injury molecule 1 (uKIM-1) for acute kidney injury (AKI) in adults. We searched PubMed and Embase for literature published up to November 1st, 2019 and used the Quality Assessment Tool for Diagnosis Accuracy Studies (QUADAS-2) to assess the quality. Then, we extracted useful information from each eligible study and pooled sensitivity, specificity, and area under the curve (AUC) values. A total of 14 studies with 3300 patients were included. The estimated sensitivity of urinary KIM-1 (uKIM-1) in the diagnosis of AKI was 0.74 (95% CrI 0.62–0.84), and the specificity was 0.84 (95% CrI, 0.76–0.90). The pooled diagnostic odds ratio (DOR) was 15.22 (95% CrI, 6.74–42.20), the RD was 0.55 (95% CrI 0.43–0.70), and the AUC of uKIM-1 in diagnosing AKI was 0.62 (95% CrI 0.41–0.76). The results of the subgroup analysis showed the influence of different factors. Urinary KIM-1 is a good predictor for AKI in adult patients with relatively high sensitivity and specificity. However, further research and clinical trials are still needed to confirm whether and how uKIM-1 can be commonly used in clinical diagnosis.
DOI: 10.1038/ki.2009.422
发表时间: 2010-04
影响因子: 19.6
作者:
Ferguson, Michael A.;Vaidya, Vishal S.;Waikar, Sushrut S.;Collings, Fitz B.;Sunderland, Kelsey E.;Gioules, Costas J.;Bonventre, Joseph V.
通讯作者: Bonventre, Joseph V.
DOI: 10.2215/cjn.04810908
发表时间: 2009-05-01
影响因子: 9.8
作者:
Han, Won K.;Wagener, Gebhard;Lee, H. Thomas
通讯作者: Lee, H. Thomas
DOI: 10.2215/cjn.00710113
发表时间: 2013-09-06
影响因子: 9.8
作者:
Susantitaphong, Paweena;Cruz, Dinna N.;Jaber, Bertrand L.
通讯作者: Jaber, Bertrand L.
DOI: 10.4103/2229-516x.205811
发表时间: 2017-04-01
影响因子: 1.1
作者:
Sinkala, Musalula;Zulu, Mildred;Nkhoma, Panji
通讯作者: Nkhoma, Panji
DOI: 10.1016/j.cnur.2018.07.001
发表时间: 2018-12-01
影响因子: 2
作者:
Farrar, Ashley
通讯作者: Farrar, Ashley